AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25652604 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm; n=45)
Number of subjects: 94
Study 25652604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)
Number of subjects: 94
Study 25652604 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)
Number of subjects: 94
Study 21910898 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of plant sterol esters daily in liquid yoghurt for 24 months
Number of subjects: 0
Study 21910898 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (yogurt not supplemented with plant sterol esters)
Number of subjects: 0
Study 18752381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (pharmacists involved in care)
Number of subjects: 179
Study 18752381 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care from physicians)
Number of subjects: 179
Study 18752381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 179
Study 18752381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 179
Study 18752381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study 17058629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg added to ongoing statin therapy
Number of subjects: 0
Study 17058629 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus statin
Number of subjects: 0
Study 17058629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus statin
Number of subjects: 0
Study 12965106 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide 120 mg
Number of subjects: 10
Study 12965106 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 10930201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication (5 microg x kg(‐1) 90 min before surgery)
Number of subjects: 41
Study 10930201 — intervention group
Group type: COMPARATOR
Intervention: No clonidine (control group)
Number of subjects: 41
Study 8737759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine solution administered locally to the stomach
Number of subjects: 4
Study 8737759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine solution administered locally to the small intestine
Number of subjects: 4
Study 8737759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine solution administered locally to the colon (two sites)
Number of subjects: 4
Study 8737759 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of nifedipine
Number of subjects: 4
Study 1448588 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired CO2 increased to restore PETCO2 to normal
Number of subjects: 9
Study 1448588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of fall of PCO2 protocols (0.1, 2.5, or 5 min)
Number of subjects: 9
Study 6367691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 21
Study 6367691 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 21
Study 29659684 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 (Ï‰‐3) fatty acids
Number of subjects: 0
Study 29659684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter chain n‐3 fatty acids from plant sources and long‐chain n‐3 fatty acids from marine sources
Number of subjects: 0
Study 29659684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary assessments by questionnaires and circulating biomarkers
Number of subjects: 0
Study 26915719 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Practice Nurse‐led telehealth rehabilitative programme
Number of subjects: 172
Study 26915719 — intervention group
Group type: COMPARATOR
Intervention: Standard follow‐up care
Number of subjects: 172
Study 24117656 — intervention group
Group type: EXPERIMENTAL
Intervention: CWMT Active
Number of subjects: 85
Study 24117656 — intervention group
Group type: COMPARATOR
Intervention: CWMT Placebo
Number of subjects: 85
Study 22660026 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 182
Study 22660026 — intervention group
Group type: EXPERIMENTAL
Intervention: AF
Number of subjects: 182
Study 22660026 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 182
Study 20669317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole ER once daily
Number of subjects: 259
Study 20669317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole IR three times daily
Number of subjects: 259
Study 20669317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 17432541 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of antioxidant and mitochondrial stimulating cream and oral administration of antioxidants and phenylalanine
Number of subjects: 100
Study 17432541 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of antioxidant and mitochondrial stimulating cream
Number of subjects: 100
Study 17432541 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study 17432541 — intervention group
Group type: COMPARATOR
Intervention: Placebo AF (application of a placebo cream and oral administration of antioxidants and phenylalanine)
Number of subjects: 100
Study 17432541 — intervention group
Group type: COMPARATOR
Intervention: Without cream AF (oral administration of antioxidants and phenylalanine)
Number of subjects: 100
Study 15710335 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy (n=7)
Number of subjects: 24
Study 15710335 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (n=7)
Number of subjects: 24
Study 15710335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 24
Study 11781125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (exact dosage and duration not specified)
Number of subjects: 59
Study 11781125 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 59
Study 11781125 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized studies
Number of subjects: 59
Study 11781125 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies meeting more quality criteria (both randomized and non-randomized)
Number of subjects: 59
Study 10520212 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine synthase D919G polymorphism (DD genotype)
Number of subjects: 607
Study 10520212 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with low B(6) levels
Number of subjects: 607
Study 10520212 — intervention group
Group type: COMPARATOR
Intervention: Thermolabile MTHFR polymorphism
Number of subjects: 607
Study 7554180 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR (10 mg given intravenously over 30 minutes)
Number of subjects: 100
Study 7554180 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR (20 mg given intravenously over 30 minutes)
Number of subjects: 100
Study 7554180 — intervention group
Group type: COMPARATOR
Intervention: Accelerated RTPA (recombinant tissue-type plasminogen activator) over 90 minutes
Number of subjects: 100
Study 7554180 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR
Number of subjects: 100
Study 7554180 — intervention group
Group type: COMPARATOR
Intervention: Accelerated RTPA
Number of subjects: 100
Study 1983493 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment modalities including ventilation, deflation of the interponate, and special dietary plan
Number of subjects: 0
Study 427400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Number of subjects: 143
Study 427400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 29319747 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation group with nursing consultations and group meetings
Number of subjects: 27
Study 29319747 — intervention group
Group type: COMPARATOR
Intervention: Control group with only nursing consultations
Number of subjects: 27
Study 29319747 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation group
Number of subjects: 27
Study 26921161 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (5-minute organ donation video on iPads)
Number of subjects: 915
Study 26921161 — intervention group
Group type: COMPARATOR
Intervention: Control (usual routine visit)
Number of subjects: 915
Study 26921161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (5-minute organ donation video on iPads)
Number of subjects: 915
Study 25511688 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping applied on the affected side using the muscle-relaxing technique
Number of subjects: 29
Study 25511688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no kinesiology taping)
Number of subjects: 29
Study 25511688 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping applied on healthy infants
Number of subjects: 29
Study 23835510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) + FTC/TDF
Number of subjects: 1096
Study 23835510 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) + FTC/TDF
Number of subjects: 1096
Study 20533765 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 250 mg
Number of subjects: 82
Study 20533765 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg
Number of subjects: 82
Study 19122337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 225 mg single dose
Number of subjects: 16
Study 19122337 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 200 mg twice daily for 7 days + Pranlukast 225 mg single dose on day 7
Number of subjects: 16
Study 16618015 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 160/120 (2 x 1 capsule/d)
Number of subjects: 140
Study 16618015 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (1 x 0.4 mg/d)
Number of subjects: 140
Study 11684627 — intervention group
Group type: EXPERIMENTAL
Intervention: B9340 (bradykinin receptor antagonist)
Number of subjects: 17
Study 11684627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9699089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro
Number of subjects: 24
Study 9699089 — intervention group
Group type: COMPARATOR
Intervention: U40 regular insulin
Number of subjects: 24
Study 9699089 — intervention group
Group type: COMPARATOR
Intervention: U100 regular insulin at 8 degrees C
Number of subjects: 24
Study 9699089 — intervention group
Group type: COMPARATOR
Intervention: U100 regular insulin at 37 degrees C
Number of subjects: 24
Study 7733610 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound (US) localization of abnormal parathyroid glands
Number of subjects: 28
Study 7733610 — intervention group
Group type: COMPARATOR
Intervention: No preoperative ultrasound (US) localization
Number of subjects: 28
Study 2689469 — intervention group
Group type: COMPARATOR
Intervention: Verapamil-SR 60 mg
Number of subjects: 221
Study 2689469 — intervention group
Group type: COMPARATOR
Intervention: Verapamil-SR 120 mg
Number of subjects: 221
Study 8134676 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1% infusion at 6 mg/kg/h for 10 minutes, then 3 mg/kg/h)
Number of subjects: 40
Study 8134676 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.3% infusion with initial bolus of 0.06 mg/kg and infusion at 0.05 mg/kg/h)
Number of subjects: 40
Study 226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Oxytetracycline
Number of subjects: 300
Study 226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-iodohydroxyquinoline and Oxytetracycline
Number of subjects: 300
Study 226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-iodohydroxyquinoline, Oxytetracycline, and Dehydroemetine
Number of subjects: 300
Study 226725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clioquinol and Oxytetracycline
Number of subjects: 300
Study 31188681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning (pure oxygen for 5 minutes prior to exercise)
Number of subjects: 17
Study 31188681 — intervention group
Group type: COMPARATOR
Intervention: Nonhyperoxic preconditioning (chamber air for 5 minutes prior to exercise)
Number of subjects: 17
Study 30444838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP < 120 mmHg)
Number of subjects: 9068
Study 30444838 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (target SBP between 135 and 139 mmHg)
Number of subjects: 9068
Study 28401876 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC (early-switch group)
Number of subjects: 553
Study 28401876 — intervention group
Group type: COMPARATOR
Intervention: Current ART (late-switch group)
Number of subjects: 553
Study 28401876 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/DTG/3TC
Number of subjects: 553
Study 28401876 — intervention group
Group type: COMPARATOR
Intervention: Current ART
Number of subjects: 553
Study 28401876 — intervention group
Group type: COMPARATOR
Intervention: Late-switch group (post-switch)
Number of subjects: 553
Study 26073022 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7 treated group (n=42)
Number of subjects: 84
Study 26073022 — intervention group
Group type: COMPARATOR
Intervention: MK-7 naïve group (n=42)
Number of subjects: 84
Study 24125483 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily for 6 weeks
Number of subjects: 32
Study 24125483 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 32
Study 21193178 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge Eating Disorder (BED) group (n = 40)
Number of subjects: 79
Study 21193178 — intervention group
Group type: COMPARATOR
Intervention: Non-binge-eating control group (n = 39)
Number of subjects: 79
Study 19106380 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 90
Study 19106380 — intervention group
Group type: COMPARATOR
Intervention: NPH/Lente insulin
Number of subjects: 90
Study 17300298 — intervention group
Group type: EXPERIMENTAL
Intervention: Head flexion position
Number of subjects: 102
Study 17300298 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral head position
Number of subjects: 102
Study 17300298 — intervention group
Group type: EXPERIMENTAL
Intervention: Head extension position
Number of subjects: 102
Study 17300298 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of flexion and neutral positions between genders
Number of subjects: 102
Study 15133820 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (non-subtype-selective opioid receptor antagonist)
Number of subjects: 14
Study 15133820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12825763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical traction plus exercise
Number of subjects: 199
Study 12825763 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 199
Study 9808908 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of copper
Number of subjects: 40
Study 9808908 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of ceruloplasmin
Number of subjects: 40
Study 9808908 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper and ceruloplasmin levels
Number of subjects: 40
Study 7667832 — intervention group
Group type: COMPARATOR
Intervention: Low-dose estrogen (0.625 mg conjugated estrogens)
Number of subjects: 83
Study 7667832 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (30-50 micrograms ethinyl estradiol daily)
Number of subjects: 83
Study 7667832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose estrogen (300 micrograms ethinyl estradiol daily)
Number of subjects: 83
Study 2654329 — intervention group
Group type: EXPERIMENTAL
Intervention: C + M (methotrexate 50 mg/m2 on days 1 and 15 plus cisplatin 80 mg/m2 on day 2 every 4 weeks)
Number of subjects: 108
Study 2654329 — intervention group
Group type: COMPARATOR
Intervention: C (cisplatin 80 mg/m2 on day 1 every 4 weeks)
Number of subjects: 108
Study 2654329 — intervention group
Group type: EXPERIMENTAL
Intervention: C + M
Number of subjects: 108
Study 2654329 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 108
Study 11425 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsalmide
Number of subjects: 16
Study 11425 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 16
Study 31361934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin
Number of subjects: 164
Study 31361934 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone
Number of subjects: 164
Study 28279941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + trastuzumab in HER2-positive cases
Number of subjects: 340
Study 28279941 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + celecoxib in HER2-negative cases
Number of subjects: 340
Study 28279941 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant trastuzumab
Number of subjects: 340
Study 26348402 — intervention group
Group type: EXPERIMENTAL
Intervention: Euvichol
Number of subjects: 1263
Study 26348402 — intervention group
Group type: COMPARATOR
Intervention: Shanchol
Number of subjects: 1263
Study 23512444 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sheet of polypropylene mesh fixed in the preperitoneal space during wound closure (Group I)
Number of subjects: 64
Study 23512444 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure (Group II)
Number of subjects: 64
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Nabiximols 10.8 mg
Number of subjects: 23
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Nabiximols 21.6 mg
Number of subjects: 23
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Nabiximols 43.2 mg
Number of subjects: 23
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol 20 mg
Number of subjects: 23
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol 40 mg
Number of subjects: 23
Study 21671456 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol (combined with placebo)
Number of subjects: 23
Study 19266699 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Impact of Genetic Testing for Alzheimer's disease (IGT‐AD) scale
Number of subjects: 276
Study 17681164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 147
Study 17681164 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 147
Study 17681164 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 147
Study 15492789 — intervention group
Group type: EXPERIMENTAL
Intervention: C1772T polymorphism in HIF‐1alpha gene in colorectal cancer patients
Number of subjects: 200
Study 15492789 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 200
Study 11480500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary antioxidants (400 IU vitamin E/500 mg vitamin C)
Number of subjects: 17
Study 11480500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air exposure)
Number of subjects: 17
Study 9972066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroblue tetrazolium test (NBT) after renal artery embolization
Number of subjects: 45
Study 9972066 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte stimulation in vitro by LPS of E. coli
Number of subjects: 45
Study 8049437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard or high-dose Ara-C together with daunorubicin and etoposide as induction chemotherapy
Number of subjects: 168
Study 3288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 3288477 — intervention group
Group type: COMPARATOR
Intervention: L-dopa (as Sinemet)
Number of subjects: 0
Study 30131049 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening ramipril and morning indapamide retard + evening amlodipine (subgroup 1A and 2A)
Number of subjects: 130
Study 30131049 — intervention group
Group type: COMPARATOR
Intervention: Morning ramipril + evening indapamide-retard and amlodipine (subgroup 1B and 2B)
Number of subjects: 130
Study 30131049 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment irrespective of salt sensitivity and dosing regimen
Number of subjects: 130
Study 27428108 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary Therapies for Labour and Birth (CTLB) protocol, which includes acupressure, relaxation, visualisation, breathing, massage, yoga techniques, and facilitated partner support, attended a two-day antenatal education programme plus standard care.
Number of subjects: 32
Study 27428108 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group).
Number of subjects: 32
Study 25641464 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Prostate Test (QPT)
Number of subjects: 64
Study 25641464 — intervention group
Group type: COMPARATOR
Intervention: IPSS‐Q8
Number of subjects: 64
Study 24036775 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 110
Study 24036775 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotomy (Control)
Number of subjects: 110
Study 20737384 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm tumescence fluid (37 degrees C)
Number of subjects: 85
Study 20737384 — intervention group
Group type: COMPARATOR
Intervention: Cold tumescence fluid (5 degrees C)
Number of subjects: 85
Study 19052245 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of physical function with feedback to the participant and the participant's family physician
Number of subjects: 265
Study 19052245 — intervention group
Group type: COMPARATOR
Intervention: Functional assessments alone
Number of subjects: 265
Study 15679556 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treatment with sulfadoxine/pyrimethamine and artesunate
Number of subjects: 169
Study 15679556 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised treatment with sulfadoxine/pyrimethamine and artesunate
Number of subjects: 169
Study 12692009 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha
Number of subjects: 18
Study 12692009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10589887 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily trimethoprim-sulfamethoxazole (160 mg/800 mg)
Number of subjects: 2625